Markets:

Overview

News

Currencies

International

Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

2.635 -0.035 (-1.31%)

Streaming Delayed Price Updated: 12:58 PM EDT, Sep 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 Next >

Protalix (PLX) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Elfabrio sales surge drives $19.9M quarterly revenue and $22.1M H1 net income.

Via The Motley Fool

Topics Earnings Intellectual Property

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 18, 2026

Via Chartmill

Discover the top movers in Wednesday's pre-market session. ↗

March 18, 2026

Via Chartmill

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy ↗

January 30, 2026

Via Stocktwits

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? ↗

October 17, 2025

Via Stocktwits

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Preview: Protalix BioTherapeutics's Earnings ↗

August 13, 2025

Via Benzinga

Preview: Protalix BioTherapeutics's Earnings ↗

November 12, 2025

Via Benzinga

Top stock movements in today's session. ↗

October 17, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Why Is Protalix BioTherapeutics Stock Falling On Friday? ↗

October 17, 2025

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.

Via Benzinga

Which stocks are gapping on Friday? ↗

October 17, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Earnings Outlook For Protalix BioTherapeutics ↗

November 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 02, 2025

Via Benzinga

Protalix Revenue Jumps 16 Percent in Q2 ↗

August 14, 2025

Via The Motley Fool

Top movers in Friday's session ↗

May 09, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Keep an eye on the top gainers and losers in Friday's session. ↗

May 09, 2025

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

May 09, 2025

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

May 09, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 09, 2025

Via Benzinga

Earnings Scheduled For May 9, 2025 ↗

May 09, 2025

Via Benzinga

Uncovering Potential: Protalix BioTherapeutics's Earnings Preview ↗

May 08, 2025

Via Benzinga

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗

May 01, 2025

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...

Via Stocktwits

Topics Stocks

Evaluating PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) using Mark Minervini’s winning stock formula ↗

April 21, 2025

A fundamental and technical analysis of (NYSEARCA:PLX): PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) may be suited for high growth investing, we'll explore why in this article.

Via Chartmill

Does PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) show the characteristics of a Minervini super stock? ↗

March 22, 2025

A fundamental and technical analysis of (NYSEARCA:PLX): Is PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) suited for high growth investing?

Via Chartmill

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond ↗

March 17, 2025

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

Via Benzinga

Earnings Scheduled For March 17, 2025 ↗

March 17, 2025

Via Benzinga

PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 14, 2024

PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.